Ionis Pharmaceuticals Inc (NASDAQ:IONS) SVP C Frank Bennett sold 12,500 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $52.50, for a total transaction of $656,250.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

C Frank Bennett also recently made the following trade(s):

  • On Tuesday, January 16th, C Frank Bennett sold 2,696 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $51.76, for a total transaction of $139,544.96.

Ionis Pharmaceuticals Inc (IONS) opened at $51.11 on Friday. The company has a quick ratio of 6.21, a current ratio of 6.25 and a debt-to-equity ratio of 1.50. The stock has a market cap of $6,170.00, a PE ratio of 365.07 and a beta of 2.53. Ionis Pharmaceuticals Inc has a twelve month low of $37.26 and a twelve month high of $65.51.

Several analysts recently commented on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a research report on Tuesday, October 17th. Zacks Investment Research downgraded shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. BidaskClub downgraded shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, December 22nd. BMO Capital Markets upped their price objective on shares of Ionis Pharmaceuticals from $64.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 8th. Finally, Morgan Stanley upped their price objective on shares of Ionis Pharmaceuticals from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 8th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $50.76.

Institutional investors and hedge funds have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC purchased a new position in shares of Ionis Pharmaceuticals in the 3rd quarter valued at about $100,000. Parallel Advisors LLC increased its holdings in shares of Ionis Pharmaceuticals by 60.3% in the 3rd quarter. Parallel Advisors LLC now owns 3,323 shares of the company’s stock valued at $182,000 after purchasing an additional 1,250 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Ionis Pharmaceuticals by 9.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock valued at $190,000 after purchasing an additional 311 shares in the last quarter. WFG Advisors LP increased its holdings in shares of Ionis Pharmaceuticals by 77.2% in the 2nd quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock valued at $193,000 after purchasing an additional 1,655 shares in the last quarter. Finally, CIBC Asset Management Inc purchased a new position in shares of Ionis Pharmaceuticals in the 3rd quarter valued at about $212,000. Institutional investors and hedge funds own 91.43% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/02/04/ionis-pharmaceuticals-inc-ions-svp-c-frank-bennett-sells-12500-shares.html.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.